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Monoamine oxidases catalyze the oxidative deamination of dietary amines and amine neurotransmitters, and
assist in maintaining the homeostasis of the amine neurotransmitters in the brain. Dysfunctions of these
enzymes can cause neurological and behavioral disorders including Parkinson’s and Alzheimer’s diseases. To
understand their physiological roles, efficient assay methods for monoamine oxidases are essential. Reviewed
in this Perspective are the recent progress in the development of fluorescent probes for monoamine oxidases
and their applications to enzyme assays in cells and tissues. It is evident that still there is strong need for a
fluorescent probe with desirable substrate selectivity and photophysical properties to challenge the much
unsolved issues associated with the enzymes and the diseases.
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Introduction
Monoamine oxidases (MAOs) are a family of FAD-
dependent enzymes found in the outer mitochondrial mem-
brane of neuronal, glial, and other mammalian cells. These
enzymes are responsible for catalyzing the oxidative de-
amination of neurotransmitters and dietary amines, regulat-
ing intracellular levels of biogenic amines.1,2 The oxidative
deamination of dopamine by MAOs is illustrated in Scheme
1. The enzyme oxidizes the amine functionality to the iminium
ion, which undergoes hydrolysis to produce the correspond-
ing aldehyde; from this aldehyde, homovanillic acid is
eventually produced by other enzymatic processes. The
enzymatic oxidation also generates hydrogen peroxide and
ammonia (in case of primary amine substrates) as the side
products, in addition to the aldehyde, and these chemicals
are known to influence the biological system involved.
Two isoenzymes of MAO (MAO-A and MAO-B) are
present in most mammalian tissues, and they show different
substrate preference and inhibitor specificities.3 MAO-A
preferentially deaminates serotonin (5-HT: 5-hydroxy-try-
ptamine), whereas MAO-B preferentially deaminates phen-
ethylamine. Both enzymes equally deaminate dopamine,
noradrenaline, adrenaline, tryptamine, and tyramine.
The C-terminal regions of human MAOs anchor the
enzyme to the mitochondrial outer membrane, and the rest of
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Scheme 1. The oxidative deamination of amines by MAOs, and a
specific example of dopamine degradation.
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the protein is exposed to the cytoplasm. MAOs are present in
most mammalian tissues, but their distribution varies from
tissue to tissue.4-6 MAOs in peripheral tissues such as the
intestine, liver, lungs, and placenta seem to protect the body
from foreign amines. The physiological functions of MAOs
in the brain are yet to be addressed, but it is suggested that
MAOs protect neurons from exogenous amines, terminate
the actions of amine neurotransmitters, and regulate the
contents of intracellular amine stores.1,2 
Crystal structures for both human MAO-A and MAO-B
are known.7-9 According to the crystal structure analysis of
human MAO-B bound with inhibitor rasagiline (which, in
turn, covalently bound to the flavin FAD coenzyme) by
Mattevi and co-workers, MAO-B has an “entrance cavity”
of 290 Å3 and a hydrophobic “substrate cavity” of 490 Å3,
showing more elongated and narrower cavity than that of the
MAO-A which has a single hydrophobic cavity of ~550
Å3.2,6 
Dysfunction of MAOs is associated with disorders in
some central and peripheral nervous systems. Extra high
MAO-B activity in the brain is associated with neurological
degenerations involving Alzheimer’s disease, Huntington’s
disease, some forms of Parkinson’s disease and normal
aging. Abnormally low MAO-A activity is associated with
depression, schizophrenia, anxiety and psychiatric disorders.10
MAO inhibitors have been clinically found to alleviate
symptoms or slow deterioration of those diseases.11 MAO-A
inhibitors are found to be effective in the treatment of panic
disorders, mixed anxiety and atypical depression, whereas
MAO-B inhibitors are used for the treatment of Alzheimer’s
and Parkinson’s (selegiline, moclobemide) diseases, also as
an alternative for migraine prophylaxis.12,13
Analytical methods for MAOs are essential for screening
of inhibitors as well as for monitoring of enzymatic activity
in complex biological systems. In this context, fluorescent
probes for MAOs can provide convenient and sensitive
tools. In this article, the recent progress in the development
of fluorescent MAO probes is overviewed. 
Assay Methods for MAO Activity
Assay methods for the MAO activity can be used for the
diagnosis of the enzyme-associated diseases and also for
screening of the enzyme inhibitors as potential drug candi-
dates. Various methods have been thus developed for assay-
ing of MAO activity: analysis of the enzymatic oxidation
products (1) by radiometry,14 and (2) by liquid chromato-
graphy and mass spectrometry;15 (3) monitoring of oxygen
consumption or hydrogen peroxide generation from the
enzymatic activity;16 (4) fluorimetric assay;17 (5) enzyme-
linked immunosorbent assay (ELISA)18 using radioisotope-
labeled substrate19 or dye-conjugated antibodies20 (Scheme
2). These methods have been used to elucidate the distribu-
tion of MAOs and their biological and physiological roles.
Among them, the fluorescent method using molecular probes
has received much attention in the last decade due to its
advantageous features such as high sensitivity, fast response,
and bioimaging capability.21 In this review, we have over-
viewed the fluorescent probes recently developed for assay-
ing and bioimaging of MAO activity.
Fluorescent Probes for MAOs
Tools enabling the detection and imaging of biological
molecules are essential in modern chemical biology. Tre-
mendous efforts have been made to develop efficient fluore-
scent probes for monitoring and imaging of various enzymes’
activity.22 The various physiological phenomena associated
with MAOs also demand appropriate fluorescent probes. A
useful strategy to develop fluorescent MAO probes is to
combine the enzymatic amine oxidation with subsequent
chemical transformations in such a way that the conversion
can induce desirable fluorescence change. The known
fluorescent probes thus can be categorized into three types
according to the reaction scheme that follows the enzymatic
oxidation step (Scheme 3).
Scheme 2. Different approaches to assay MAO activity. 
Scheme 3. Fluorescent MAO probes categorized by the chemical
conversion following the enzymatic reaction.
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Type 1. In 2005, Sames and co-workers reported the first
reaction-based fluorescence sensing scheme for MAO probes,
which was based on the (o-aminoethyl)aniline moiety as the
reactive site (probe 1, 2; Scheme 4).23 The enzymatic oxida-
tion of the alkylamine produced the corresponding aldehyde
intermediate, which subsequently underwent intramolecular
condensation by the arylamine to form the indole ring. This
chemical conversion resulted in turn-on fluorescence change,
because the (o-aminoethyl) aniline moiety acted as fluore-
scence quencher through the photo-induced electron-transfer
(PET) process24 but its end-product indole did not act as a
PET quencher. It should be noted that an amine that has
nitrogen lone pair electrons with a low oxidation potential
readily acts as the PET quencher.
Probe 1 was able to sense MAO activity by producing the
highly fluorescent indole product through the enzymatic
oxidation followed by the intramolecular condensation;
however, it turned out to be a poor substrate for either MAO-
A or MAO-B. Interestingly, probe 2 showed good selectivity
to MAOs, showing Km values of 31 ± 2 μM for MAO-A and
510 ± 40 μM for MAO-B, respectively. They also synthe-
sized several derivatives of probe 2 and examined their
photophysical properties. Among them, only the pyrrolo[g]-
coumarin derivative showed strong fluorescence toward
MAOs, but not the pyrrolo[h]coumarin and pyrrolo[ f ]cou-
marin derivatives.
Type 2. Another clever approach to sense MAO activity
was disclosed in 2006 by Wood and co-workers, who intro-
duced (3-aminopropyloxy)arene as the reactive substrate of
the enzymes (probes 3 and 4, Scheme 5).25 Although bio-
logical substrates of MAOs have common structural features
of (2-amionoethyl)arene (dopamine, noradrenaline, adrena-
line, serotonin, 2-phenylethylamine, tryptamine, tyramine,
etc) or (aminomethyl)arene (benzylamine), they demonstrated
that (3-aminopropyloxy)arene can be the enzyme substrate,
which opened up a versatile route to develop fluorescent
sensing systems for MAOs. Crystallographic studies7-9 sug-
gest that MAOs’ binding pockets are not so tight that they
can accommodate abiotic amine substrates with a longer
alkyl chain and sterically more demanding substrates than
the natural substrates. It is suggested that MAO-A can
accommodate sterically bulkier amine substrates, whereas
MAO-B has a rather narrow and tighter binding pocket.
MAOs thus transformed the propylamine moiety in
luciferin derivative 3 or 4 into the corresponding iminium
ion, which readily underwent β-elimination to release luciferin
which was in turn elaborated to emit bioluminescence by the
luciferase activity. Such luciferin−luciferase coupled assays
often provide a low background signal and high sensitivity,
and thus have been utilized in various biological assays.26
The amine substrates of primary (3a, 4a), secondary (3b,
4b), or tertiary (3c, 4c) exhibited different reactivity toward
MAOs: tert-amine 3c was selectively recognized by MAO-
B, but pri-amine 4a and tert-amine 4c were preferentially
recognized by MAO-A. Among them, sec-amine 4b exhibit-
ed the largest signal-to-background ratio and a low level of
Km value (1.56 ± 0.13 mM).
By following the Wood’s work, Chang devised resorufin-
derived 3-aminopropyl ethers 5 as turn-on fluorescent probes
for MAOs.27 It is known that fluorophores such as resorufin,
fluoresceins, and 7-hydroxycoumarns give turn-on type
fluorescence change when the hydroxyl group in its ether
form undergoes deprotection to the free hydroxyl group.
Other related fluorescent probes have been developed based
on this sensing strategy.28,29 Accordingly, resorufin aminopropyl
Scheme 4. Fluorescent probes based on the enzymatic oxidation
followed by an intramolecular cyclization.
Scheme 5. Fluorescent MAO probes based on the enzymatic
oxidation followed by β-elimination.
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ethers 5 underwent the aforementioned enzymatic oxidation
followed by β-elimination to generate highly fluorescent
resorufin, fulfilling the turn-on sensing scheme. This sensing
scheme has proven to be versatile in the development of
other types of aryl aminopropyl ethers as fluorescent MAO
probes. Both sec-amine 5a and pri-amine 5b responded to
MAO-A and MAO-B with turn-on fluorescence change
(excitation at λex = 544 nm; emission collected at λem = 590
nm). The Michaelis–Menten constants for 5a and 5b with
MAO-A and MAO-B were obtained in pH 7.4 HEPES (100
mM) containing 5% glycerol and 1% DMSO, which were
lower than those obtained with natural amine substrates: Km
(5a/MAO-A) = 7.6 ± 10 µM, Km (5a/MAO-B) = 1.8 ± 0.2
µM, Km (5b/MAO-A) = 6.3 ± 0.6 µM, and Km (5b/MAO-B)
= 3.4 ± 0.5 µM. Probes 5a and 5b were applied to fluore-
scent imaging of MAO activity in live PC12 cell line, which
was chosen for its high endogenous expression of MAO and
neuron-like characteristics in culture when supplemented
with nerve growth factor (NGF). In the presence of pargy-
line, a MAO inhibitor, the cellular fluorescence intensity
was suppressed to an half of that obtained in the absence of
the inhibitor. 
Zhu and co-workers subsequently developed 7-hydroxy-
coumarin-derived aminopropyl ether 6 as a fluorescent
MAO probe. Probe 6 responded to MAOs with fluorescence
turn-on change (λex = 360 nm; λem = 460 nm).30 Interestingly,
probe 6 showed similar kinetic parameters toward the two
isoenzymes: Km (6/MAO-A) = 62.37 ± 3 mM and Km (6/
MAO-B) = 83.50 ± 4.0 mM, obtained for the enzymes by
mitochondrial preparations and in a borate buffer containing
BSA (20 mg/mL). They also reported fluorescein-derived
probes 7, which were used to bioimaging of MAO activity in
MCF-7 cells (human breast carcinoma cells).31 
Xing and co-workers followed a similar approach to
develop quinazolinone (HPQ)-derived aminopropyl ethers
8a−8c as fluorescent MAO probes.32 The HPQ dye shows
great photostability, a large Stokes shift (> 100 nm), and
strong fluorescence in the solid state owing to the intramole-
cular hydrogen bonding, but it is generally insoluble in
water. Upon treatment with MAOs, probes 8 underwent the
amine oxidation and subsequent β-elimination to release
HPQ precipitates, which emitted green fluorescence (λex =
360 nm; λem = 530 nm). Interestingly, in this case only pri-
amine 8a and tert-amine 8c gave significant fluorescence
change, but sec-amine 8b gave a little fluorescence change
upon treatment with MAOs. The kinetics parameters deter-
mined in the case of pri-amine 8a to be: Km (MAO-A) =
146.1 ± 7.21 μM, Kcat (MAO-A) = 9.76 ± 0.49 min−1, Km
(MAO-B) = 106.8 ± 5.06 μM, and Kcat (MAO-A) = 8.47 ±
0.42 min−1. In live cell imaging experiments with incubation
of 8a (100 µM) in DMEM (Dulbecco’s Modified Eagle
Medium) at 37 °C for 1 h, strong green fluorescence was
observed in the case of the PC12 cell line but weak fluore-
scence in the case of the C6 glioma cell line that has no
expression of MAOs. No obvious fluorescence resulted in
when PC12 cells were pretreated with a MAO-A inhibitor
clorgyline (100 mM), whereas strong fluorescence remained
when the cells were pretreated with a MAO-B inhibitor
pargyline; these results suggested that PC12 cells mainly
expressed MAO-A enzyme.
Type 3. Ahn and co-workers disclosed a new sensing
scheme for MAOs, which involved the amine oxidation,
followed by followed by β-elimination and subsequent an
intramolecular condensation. The resulting probes 9a (pri-
amine) and 9b (sec-amine) produced a linear benzocoumarin
dye, named IminoPOS, which showed promising two-photon
absorption and emission properties for bioimaging application
(Scheme 6).33,34 As a result, probes 9 enabled them to obtain
fluorescent images of live cells by two-photon microscopy
(TPM) for the first time. Two-photon excitation of dyes
provides several advantageous features in bioimaging such
as focal point excitation with 3D imaging, deep tissue imag-
ing, less photo-damage and photo-bleaching to samples.35,36
Accordingly, various two-photon fluorescent probes have
been developed in last decade, notably those acedan-based
probes intensively studied by Cho and co-workers.37,38 Such
two-photon probes are promising for in vivo monitoring of
MAO activity in deep tissues.
Both pri-amine 9a and sec-amine 9b showed turn-on
fluorescence response toward MAO-A and MAO-B respec-
tively (λex = 448 nm; λem = 585 nm). The kinetics analysis of
probes 9 with MAOs showed a moderate level of Km values:
Km (9a/MAO-A) = 70 μM, Km (9a/MAO-B) = 75 μM, Km
(9b/MAO-A) = 252 μM, and Km (9b/MAO-B) = 210 μM,
obtained in pH 7.4 HEPES (100 mM) containing 5%
glycerol and 1% DMSO at 37 °C. Enzyme inhibition assays
with pri-amine 9a (at the Km concentration) toward MAO-A
and MAO-B in the absence and presence of inhibitors
showed that moclobemide inhibited 50% of the MAO-A
activity and 20% of MAO-B activity, whereas pargyline
inhibited MAO-A slightly but 80% of MAO-B activity; these
results are similar to the reported inhibitor assay data for
MAOs. Further investigation of pri-amine 9a in two-photon
imaging of MAOs in live cells was carried out using the
chromaffin cell line that expressed a high level of MAOs,
together with the C6 glioma cell line that expressed little
MAOs. The TPM image data showed that chromaffin cells
pretreated with 9a showed strong red fluorescence, whereas
Scheme 6. Two-photon fluorescent probes based on the enzymatic
oxidation, followed by β-elimination and subsequent intramole-
cular cyclization.
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the cells pretreated with pargyline showed little fluorescence
(λex = 900 nm, 10 mW laser power). It is notable that
IminoPOS has a larger two-photon absorption cross-section
(TPACS) value (180 GM), higher fluorescence quantum
yield (ΦF = 63%), and a longer maximum absorbance wave-
length (λmax = 448 nm), compared with acedan, a widely
used in two-photon excitable probes, which properties are
promising for the development of new two-photon probes of
other biological targets.
MAO-B Selective Fluorescent Probes. MAO-A is mainly
expressed in catecholaminergic neurons and metabolizes
several different neurotransmitters. MAO-B, on the other
hand, is primarily found in astrocytes and serotonergic
neurons, and acts on dopamine and β–phenylethylamine.39
These isoenzymes assist in maintaining the homeostasis of
amine neurotransmitters in the brain. But, older people or
patients with Parkinson’s disease (PD) and Alzheimer’s di-
sease (AD) show overexpression of MAO-B, but not MAO-
A. The main pathology of PD is the loss of dopaminergic
neurons due to the overexpression of MAO-B, causing
autonomic dysfunction and neuropsychiatric problems.40
Several previous studies reported increased activities of
MAO-B in the brain and blood platelets of AD patients. The
increase of MAO-B in the brain, predominantly in plaque-
associated astrocytes in neuropathologically verified AD
brains, is most likely due to transcriptional elevation of
MAO-B protein. However, the exact reason that increased
activity of MAO-B is still unknown.41,42 Given that the
expression level and the substrate specificity of MAO-A and
MAO-B are different, it is necessary to develop fluorescent
probes that discriminate one isoform of the enzymes from
the other.
Castagnoli and co-workers reported that a pyrrole-contain-
ing 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
10 underwent the enzymatic oxidation selectively with MAO-
B in mouse brain samples to produce a dihydropyridinium
compound 11, which absorbed at 420 nm (Scheme 7).43 The
MPTP moiety was previously known to induce dopaminergic
neurotoxicity, as MAO-B, not MAO-A, oxidized it.44 The
colorimetric sensing scheme was subsequently adopted by
others to develop fluorescent probes selective to MAO-B.
Zhu and co-workers reported coumarin-derived MPTP
derivatives 12 as turn-on fluorescent probes for MAO-B (λex
= 360 nm; λem = 460 nm) (Scheme 8).45 Upon oxidation of
the MPTP moiety by the enzyme, probe 12 produced the
corresponding dihydropyridinium intermediate, which sub-
sequently underwent the hydrolytic ether cleavage to release
the fluorescent coumarin dye. Probe 12a showed high selec-
tivity toward MAO-B, with Km value of 59.63 μM. From a
molecular docking study with probe 12 and MAO-A or
MAO-B active site, they found hydrogen bonding between
the probe nitrogen and the hydroxyl group of Tyr60 in the
active site of MAO-B, but no such hydrogen bonding in the
case of MAO-A. The calculated binding energy of the probe
with MAO-A was found to be much higher than that with
MAO-B (> 1000 kcal mol−1 vs. 10.2 kcal mol−1). In a further
study, they reported fluorescein derivatives 13 and their use
for bioimaging.46 Probe 13a, however, gave only about three
times higher fluorescence enhancement to MAO-B over
MAO-A (Km (13a/MAO-A) = 257.9 μM, Km (13a/MAO-B)
= 47.1 μM).
Recently, Yao and co-workers disclosed a MAO-B selective
two-photon fluorescent probe, which is an aminopropyl
carbamate of acedan.47 Probe 14 was thus used to fluore-
scently image MAO-B specific activities present in mam-
malian proteome lysates, live cells and mouse tissues, and a
parkin-related insect PD model. Furthermore, they assessed
MAO-B activities in proteome lysates prepared from B
lymphocytes and also from fibroblasts, both derived from
PD patients. They observed that there was an obvious
increase in MAO-B expression in the case of lymphocytes
whereas little change in the cased of fibroblasts, compared
with controls. They concluded that the difference in MAO-B
activity profiles between control and PD patients are cell-
type-specific, which may be potentially used as a convenientScheme 7. MAO-B selective substrate and a colorimetric probe.
Scheme 8. Fluorescent probes selective to MAO-B.
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surrogate biomarker for PD diagnosis. 
Conclusion
Monoamine oxidases, MAO-A and MAO-B together, are
thought to maintain the homeostasis of neurotransmitters in
the brain by breaking down amine neurotransmitters. Dys-
function of MAOs can cause neurological and behavioral
disorders. Aberrant expression of MAO-B is observed in
patients of Parkinson’s disease and Alzheimer’s disease.
MAO-B inhibitors are used to attenuate the progress of
Parkinson’s disease. However, our present understanding on
the mechanism of cytoprotective actions of MAOs is limit-
ed. Also, it is unclear why MAO activity increases in the
brain of those patients and what regulates its activity. A
selective and sensitive fluorescent probe with the deep tissue
imaging capability may aid us to investigate these issues. In
this context, it is promising to see a significant progress in
the development of fluorescent probes for MAOs in recent
years. In particular, two-photon fluorescent probes are pro-
mising for future applications to address those fundamental
issues. As noted by Yao and co-workers, a small-molecule
fluorescent probe may be applied for the simple and conv-
enient diagnosis of Parkinson’s disease in near future. We
hope that this review article stimulates chemists to develop
efficient fluorescent MAO probes and to apply them to
challenge those unsolved issues.
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